异动解读 | 和铂医药慢性阻塞性肺病新药获批临床试验引发股价大涨5.66%

异动解读
05 Feb

2025年2月5日周三,和铂医药-B(02142)盘中大涨5.66%,引发市场关注。

公司当日发布公告,旗下针对胸腺基质淋巴细胞生成素(TSLP)的全人源抗体HBM9378/SKB378(又称WIN378)已获准中国国家药品监督管理局(NMPA)的新药研究申请(IND)批件,可开展临床试验研究,用于治疗慢性阻塞性肺病(COPD)。

消息指出,该新药系和铂医药与四川科伦博泰生物医药共同开发项目,双方在大中华区和部分东南亚、西亚地区享有权利。根据早前与Windward Bio AG的授权协议,和铂医药和科伦博泰有机会获得最高9.7亿美元的预付款及里程碑付款,以及产品净销售额的单双位数百分比特许权使用费。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10